By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sangamo Therapeutics (Formerly Known As Sangamo BioSciences, Inc.) 

501 Canal Boulevard
Suite A100
Richmond  California  94804  U.S.A.
Phone: 510-970-6000 Fax: 510-236-8951


Key Statistics

Ownership: Public

Web Site: Sangamo Therapeutics
Symbol: SGMO


Company News
Sangamo Therapeutics (SGMO) Announces Presentation Of New Data Demonstrating Significant Reduction Of Tau Expression Using Proprietary ZFP Gene Regulation Technology 3/29/2017 8:29:08 AM
Sangamo Therapeutics (SGMO) Receives Orphan Drug Designation From The FDA For SB-913 Genome Editing Treatment For MPS II 3/1/2017 7:13:33 AM
Sangamo Therapeutics (SGMO) Reports Fourth Quarter And Full Year 2016 Financial Results 2/28/2017 8:29:19 AM
Sangamo Therapeutics (SGMO) Announces Chief Financial Officer Succession 2/28/2017 8:06:42 AM
Sangamo Therapeutics (SGMO) Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I 2/27/2017 6:48:22 AM
Sangamo Therapeutics (SGMO) Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast 2/22/2017 8:42:56 AM
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017 6:00:10 AM
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017 6:46:05 AM
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 1/5/2017 6:33:43 AM
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting 12/6/2016 8:30:13 AM